Cleveland BioLabs to Present at Rodman & Renshaw 9th Annual Healthcare Conference

< p > < p class='stdBody' > Cleveland BioLabs, Inc. (NASDAQ: CBLI) (BOST: CBLI) today announced that the Company is scheduled to present at the Rodman & amp; Renshaw 9th Annual Global Healthcare Conference, on November 5-7, in New York City. < /p > < p class='stdBody' > Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is an orally administered small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has an ongoing Phase II trial with CBLC102 in hormone refractory prostate cancer and will begin a second Phase II trial in Renal Cell Carcinoma in late 2007. < /p > < p class='stdBody' > Source: The Global Consulting Group < /p > < /p > < p > 10/22/2007 < /p >
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news